Absolute and relative psoriasis area and severity indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis :

Información:
Discusión (0)
Estadísticas de uso

Absolute and relative psoriasis area and severity indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis : An integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes - Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Dossenbach, Martin (Eli Lilly and Company) ; Berggren, Lovisa (Lilly Deutschland GmbH) ; Ljungberg, Anders (Eli Lilly and Company) ; Zachariae, Claus (University of Copenhagen) ; Universitat Autònoma de Barcelona

Comentarios (0) | Reseñas (0)

Inicie un debate sobre cualquier aspecto de este documento.

Registros similares

Añadir comentario